1Saraiva L, Cunha RN, Jesus D, et al. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study. Rheumatology (Oxford). 2023. doi:10.1093/rheumatology/kead353. Online ahead of print.
10.1093/rheumatology/kead353
Web of Science® Google Scholar
2Assunção H, Jesus D, Larosa M, et al. Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. Rheumatology (Oxford). 2022; 61(8): 3309-3316. doi:10.1093/rheumatology/keab895
10.1093/rheumatology/keab895
CAS PubMed Web of Science® Google Scholar
3Shin JI, Lee KH, Park S, et al. Systemic lupus erythematosus and lung involvement: a comprehensive review. J Clin Med. 2022; 11(22): 6714. doi:10.3390/jcm11226714
10.3390/jcm11226714
CAS PubMed Web of Science® Google Scholar
4Jesus D, Larosa M, Henriques C, et al. Systemic lupus erythematosus disease activity score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. Ann Rheum Dis. 2021; 80(12): 1568-1574. doi:10.1136/annrheumdis-2021-220363
10.1136/annrheumdis-2021-220363
CAS PubMed Web of Science® Google Scholar
5Colquhoun M, Akram S. Shrinking Lung Syndrome. StatPearls. StatPearls Publishing; 2023.
Google Scholar
6Almajed MR, Obri MS, Mahmood S, Demertzis ZD. Shrinking lung syndrome in a young female: a rare pulmonary manifestation of systemic lupus erythematosus. Cureus. 2022; 14(4):e24320. doi:10.7759/cureus.24320
10.7759/cureus.24320
PubMed Web of Science® Google Scholar
7Goswami RP, Mondal S, Lahiri D, et al. Shrinking lung syndrome in systemic lupus erythematosus successfully treated with rituximab. QJM. 2016; 109(9): 617-618. doi:10.1093/qjmed/hcw093
10.1093/qjmed/hcw093
CAS PubMed Google Scholar
8DeCoste C, Mateos-Corral D, Lang B. Shrinking lung syndrome treated with rituximab in pediatric systemic lupus erythematosus: a case report and review of the literature. Pediatr Rheumatol Online J. 2021; 19(1): 7. doi:10.1186/s12969-020-00491-0
10.1186/s12969-020-00491-0
PubMed Web of Science® Google Scholar
9Teng YKO, Bruce IN, Diamond B, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019; 9(3):e025687. doi:10.1136/bmjopen-2018-025687
10.1136/bmjopen-2018-025687
PubMed Web of Science® Google Scholar
10Jones A, Muller P, Dore CJ, et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019; 9(12):e032569. doi:10.1136/bmjopen-2019-032569
10.1136/bmjopen-2019-032569
PubMed Web of Science® Google Scholar
11Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis [published correction appears in arthritis Rheumatol. 2021 Dec;73(12):2356]. Arthritis Rheumatol. 2021; 73(1): 121-131. doi:10.1002/art.41466
10.1002/art.41466
CAS PubMed Web of Science® Google Scholar

Volume27, Issue3

March 2024

e15110

Combination treatment with rituximab and belimumab in shrinking lung syndrome in systemic lupus erythematosus

CONFLICT OF INTEREST STATEMENT

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Combination treatment with rituximab and belimumab in shrinking lung syndrome in systemic lupus erythematosus

CONFLICT OF INTEREST STATEMENT

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

References

Related

Information